Roivant Sciences Ltd.
GBFinancials
Valuation Metrics
Roivant Sciences Ltd.'s Market Cap is $23.97B. At end of 2025 it was $15.12B. Ranked #547 of 3,112 in US market (top 18%), #167 of 1,445 on NASDAQ (top 12%), #25 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 9%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $23.97B | US#547/3,112 Sec#25/269 |
| Revenue | $8M | US#2,927/3,112 Sec#183/269 |
| Net Income | $-300M | US—/3,112 Sec—/269 |
| Total Assets | $5.73B | US#1,340/3,112 Sec#36/269 |
| Net Assets | $4.53B | US#757/3,112 Sec#32/269 |
| Employees | 750 | US#1,302/3,112 Sec#40/269 |
| Value | ||
| P/B | 5.29x | US#2,223/3,112 Sec#146/269 |
| P/S | 2901.46x | US#2,958/3,112 Sec#203/269 |
| FCF Yield | -3.17% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -6.62% | US#2,349/3,112 Sec#86/269 |
| ROA | -5.23% | US#2,530/3,112 Sec#93/269 |
| Op. Margin | -15560.57% | US#2,963/3,112 Sec#199/269 |
| Revenue Growth | -66.71% | US#2,895/3,112 Sec#169/269 |
| Financial Health | ||
| Debt Ratio | 9.62% | US#103/3,112 Sec#45/269 |
| Total Debt | $107M | US#2,360/3,112 Sec#115/269 |
| FCF | $-759M | US#2,864/3,112 Sec#264/269 |
| Cash | $1.42B | US#540/3,112 Sec#28/269 |
| Current Ratio | 18.37x | US#135/3,112 Sec#37/269 |
| Performance | ||
| 1Y Return | 194.61% | US#112/3,112 Sec#39/269 |
| 1M Return | -5.15% | US#2,254/3,112 Sec#127/269 |
| From 52W High | -9.95% | US#1,039/3,112 Sec#52/269 |
| 1Y MDD | -12.84% | US#181/3,112 Sec#5/269 |
| Trading | ||
| Volume | 5,001,143 shares | US#368/3,112 Sec#27/269 |
| Trading Value | $165M | US#606/3,112 Sec#36/269 |
| Per Share | ||
| EPS | $-1.16 | US—/3,112 Sec—/269 |
| BPS | $6.13 | US#2,119/3,112 Sec#113/269 |
Company Info
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.